(Q33936572)

English

Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group (English)

1 reference

Europe PubMed Central

30 July 2017

0 references

author name string

Patel R

1

1 reference

Europe PubMed Central

30 July 2017

Bodsworth NJ

2

1 reference

Europe PubMed Central

30 July 2017

Woolley P

3

1 reference

Europe PubMed Central

30 July 2017

Peters B

4

1 reference

Europe PubMed Central

30 July 2017

Vejlsgaard G

5

1 reference

Europe PubMed Central

30 July 2017

Saari S

6

1 reference

Europe PubMed Central

30 July 2017

Gibb A

7

1 reference

Europe PubMed Central

30 July 2017

Robinson J

8

1 reference

Europe PubMed Central

30 July 2017

publication date

1 April 1997

1 reference

Europe PubMed Central

30 July 2017

Genitourinary medicine

1 reference

Europe PubMed Central

30 July 2017

73

1 reference

Europe PubMed Central

30 July 2017

2

1 reference

Europe PubMed Central

30 July 2017

105-109

1 reference

Europe PubMed Central

30 July 2017

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Safety of acyclovir: a summary of the first 10 years experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Efficacy of oral acyclovir treatment of acute herpes zoster.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Long-term suppression with oral acyclovir of recurrent herpes simplex virus infections in otherwise healthy patients. A European multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Acyclovir: A Decade Later

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

5 July 2018

Tables of the number of patients required in clinical trials using the logrank test.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

29 October 2018

A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195782

29 October 2018

Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/9215091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of herpes zoster with oral acyclovir

1 reference

https://pubmed.ncbi.nlm.nih.gov/9215091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/9215091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral acyclovir in the treatment of herpes zoster in general practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/9215091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral acyclovir suppressive therapy in severe recurrent genital herpes. A double-blind, placebo-controlled cross-over study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9215091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of prescribed daily dose frequency on patient medication compliance

1 reference

https://pubmed.ncbi.nlm.nih.gov/9215091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9215091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33936572&oldid=1989432767"